Pancreatic islet cell tumors

Search Trials
Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Mar 5, 2013
Disease(s):
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention(s):
temozolomide or dacarbazine-based chemotherapy, endostatin
177Lutethium – Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Status:
Recruiting
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Gastro-entero-pancreatic Neuroendocrine Tumors
Intervention(s):
CapecitabineLu-PRRTSS-LAR
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Status:
Recruiting
Last Changed:
Jan 1, 1970
First Changed:
Nov 11, 2014
Disease(s):
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Intervention(s):
lanreotidePlacebo
Asymptomatic Small Pancreatic Endocrine Neoplasms.
Status:
Recruiting
Last Changed:
Aug 8, 2018
First Changed:
Jan 1, 1970
Disease(s):
Non Functioning Pancreatic Endocrine Tumor
Intervention(s):
Radiological imaging studiesQuality of Life Assessment
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Dec 5, 2010
Disease(s):
Pancreatic Neuroendocrine Tumors
Intervention(s):
Sunitinib

Connect. Empower. Inspire.